Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOAR trial of eltrombopag + cyclosporine as first-line therapy for severe acquired aplastic anemia
2016-002814-29Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Dec 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag and cyclosporine in acquired aplastic anemia (AAA) and aplastic anemia, sponsored by Novartis. Started Dec 2016; status: recruiting.
02
Drugs
eltrombopagcyclosporine
03
Conditions
acquired aplastic anemia (AAA)aplastic anemia
Beyond the preview
Go deeper on 2016-002814-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002814-29.